Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 08, 2022

BUY
$48.29 - $71.27 $37,666 - $55,590
780 Added 25.2%
3,875 $201,000
Q2 2022

Aug 10, 2022

BUY
$38.13 - $76.93 $17,768 - $35,849
466 Added 17.73%
3,095 $146,000
Q1 2022

May 02, 2022

BUY
$56.06 - $74.11 $9,530 - $12,598
170 Added 6.91%
2,629 $187,000
Q4 2021

Feb 03, 2022

BUY
$60.19 - $97.37 $3,611 - $5,842
60 Added 2.5%
2,459 $184,000
Q3 2021

Nov 10, 2021

SELL
$41.02 - $58.65 $6,440 - $9,208
-157 Reduced 6.14%
2,399 $136,000
Q2 2021

Aug 06, 2021

BUY
$43.76 - $53.11 $6,914 - $8,391
158 Added 6.59%
2,556 $112,000
Q1 2021

May 13, 2021

BUY
$41.69 - $54.95 $6,920 - $9,121
166 Added 7.44%
2,398 $118,000
Q4 2020

Feb 12, 2021

BUY
$41.16 - $47.47 $3,210 - $3,702
78 Added 3.62%
2,232 $94,000
Q3 2020

Nov 13, 2020

BUY
$43.36 - $53.53 $58,926 - $72,747
1,359 Added 170.94%
2,154 $99,000
Q2 2020

Aug 06, 2020

BUY
$46.37 - $57.58 $4,497 - $5,585
97 Added 13.9%
795 $40,000
Q1 2020

May 11, 2020

BUY
$40.22 - $62.0 $5,309 - $8,184
132 Added 23.32%
698 $36,000
Q4 2019

Feb 11, 2020

SELL
$57.95 - $66.61 $1,680 - $1,931
-29 Reduced 4.87%
566 $35,000
Q3 2019

Nov 14, 2019

BUY
$60.08 - $88.17 $1,381 - $2,027
23 Added 4.02%
595 $36,000
Q2 2019

Aug 12, 2019

BUY
$81.3 - $97.35 $9,918 - $11,876
122 Added 27.11%
572 $48,000
Q1 2019

May 13, 2019

BUY
$69.08 - $105.66 $4,144 - $6,339
60 Added 15.38%
450 $43,000
Q4 2018

Feb 12, 2019

BUY
$65.41 - $84.65 $5,952 - $7,703
91 Added 30.43%
390 $28,000
Q3 2018

Nov 13, 2018

BUY
$85.46 - $126.37 $21,023 - $31,087
246 Added 464.15%
299 $26,000
Q2 2018

Aug 09, 2018

BUY
$81.85 - $120.51 $4,338 - $6,387
53 New
53 $6,000

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $194M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Mutual Of America Capital Management LLC Portfolio

Follow Mutual Of America Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mutual Of America Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mutual Of America Capital Management LLC with notifications on news.